I also bought into BOT. This is a departure from mining and exploration and into pharma.
I liked BOT because they have a proven product that is going through the FDA approval process. The product is already selling well in Japan. How well? BOT gets a % revenue from all Japanese sales and this is likely to be announced soon. It has been indicated that the announcement could be as early as Feb 3. Once this revenue is announced, the share price should jump.
If I hold on for longer, it would be to take advantage of the inevitable share price explosion when FDA approval is granted (and why wouldn't they get the approval, the product is already selling well in Japan and has achieved goor trial results in Australia).
Yes, there are risks; there ae risks with anything, including crossing the road.
Comments
Post a Comment